Press release
RNAi Therapeutics and Technology Market Key Players Analysis - Alnylam, Novartis, Novo Nordisk, Regulus therapeutics, miRagen therapeutics.
RNAi Therapeutics and Technology Market
According to the latest research by InsightAce Analytic, the RNAi Therapeutics and Technology Market is valued at US$ 1.49 Bn in 2023, and it is expected to reach US$ 5.02 Bn by 2031, with a CAGR of 16.6% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2508
RNA interference (RNAi) is a sophisticated biological process that plays a critical role in the regulation of gene expression through sequence-specific silencing. This natural mechanism has facilitated the development of RNAi-based therapeutics, an innovative class of treatments that harness the inherent properties of RNAi to regulate cellular expression systems. The therapeutic applications of RNAi extend across a broad spectrum of medical conditions, including metabolic disorders, chronic diseases, and cancer, positioning RNAi therapeutics as a leading area of biomedical research and development.
RNAi-based therapies provide a targeted and precise approach to treating diseases by utilizing the cell's intrinsic gene-silencing capabilities. These therapies are categorized into various types, such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and microRNAs (miRNA), each of which employs different mechanisms to regulate gene expression, influence protein synthesis, and selectively silence genes associated with disease. The ability of RNAi therapeutics to precisely control gene activity, regulate protein translation, and address complex pathological conditions highlights their potential as transformative solutions in the field of modern medicine.
List of Prominent Players in the RNAi Therapeutics and Technology:
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma
• Dicerna Pharmaceuticals (Novo Nordisk A/S)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Glaxosmithkline Plc.
• Ionis Pharmaceuticals (U.S.)
• Moderna, Inc.
• Olix Pharmaceuticals, Inc.
• Quark Software Inc. (U.S.)
• Rexahn Pharmaceuticals, Inc.
• Sanofi
• Silence Therapeutics
• Thermo Fisher Scientific Inc.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers
The global RNAi therapeutics market is expanding primarily due to the rising incidence of chronic diseases, including cardiovascular disorders, cancer, diabetes, tuberculosis (TB), and AIDS. RNA-based therapies offer significant potential in addressing a wide range of chronic, genetic, and rare conditions. According to the World Health Organization (WHO), cardiovascular diseases account for approximately 17.9 million deaths annually, followed by cancer (9.3 million deaths), chronic respiratory diseases (4.1 million deaths), and diabetes (2 million deaths). The growing urgency to develop innovative treatments is accelerating the adoption of RNAi technology, which is playing a crucial role in advancing personalized medicine and molecular diagnostics. Furthermore, high-throughput techniques that identify altered cellular molecules and metabolites are enhancing the application of RNAi in cancer diagnostics and therapies, marking a significant shift towards precision medicine.
Challenges
Despite the promising potential of RNAi therapeutics, the market faces several challenges, particularly in drug delivery mechanisms. The introduction of RNA molecules into target cells may provoke immune responses, compromising therapeutic efficacy. Additionally, exogenous RNA is highly susceptible to rapid degradation by RNases present in biological tissues, which undermines its stability. The negative charge of RNA further complicates its ability to traverse the hydrophobic cytoplasmic membrane, limiting efficient cellular uptake. Large-scale manufacturing also remains complex and resource-intensive, necessitating further technological advancements to improve production efficiency. Another concern is the immunogenicity of exogenous RNA, which can lead to cell toxicity and inhibit therapeutic protein translation, adding complexity to the clinical development of RNAi-based treatments.
Regional Trends
North America, particularly the United States, leads in RNAi therapeutic advancements, driven by several key factors. The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders has heightened the demand for innovative treatment options. Notably, approximately 40% of American adults suffer from multiple chronic conditions, further fueling the demand for RNAi-based therapies. Significant investment from pharmaceutical companies, government agencies, and private stakeholders is supporting research, development, and commercialization efforts in the region. The gene editing sector has also attracted substantial funding from venture capitalists and federal agencies, bolstering industry progress. Additionally, North America benefits from a strong regulatory framework, with agencies like the U.S. Food and Drug Administration (FDA) facilitating the approval and adoption of advanced RNAi therapeutics, reinforcing the region's leadership in this market.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2508
Recent Developments:
• In April 2024, Medison Pharma and Alnylam Pharmaceuticals, Inc. expanded their partnership to include selected markets in LATAM, APAC, and additional international markets, in addition to Central & Eastern Europe and Israel. This collaboration will allow companies to expand their footprint and provide the advantages of Alnylam's innovative RNAi treatments to patients in more APAC and LATAM regions.
• In November 2021, Arrowhead Pharmaceuticals linked an exclusive license deal with GlaxoSmithKline (GSK) for their experimental RNA interference (RNAi) therapeutic, ARO-HSD. GSK will lead the development and commercialization of ARO-HSD for treating nonalcoholic steatohepatitis (NASH). ARO-HSD targets HSD17B13 and holds promise as a therapy for both alcohol-related and nonalcohol-associated liver diseases, including NASH.
Segmentation of RNAi Therapeutics and Technology Market-
By Type
• Small interfering RNA (siRNA)
• MicroRNA (miRNA)
By Application
• Genetic Disorders
• Oncology
• Neurodegenerative Disorders
• Infectious Diseases
• Renal Diseases
• Others
By Route of Administration
• Intradermal Injections
• Pulmonary Delivery
• Intravenous Injections
By End-User
• Diagnostic Laboratories
• Research and Academic Laboratories
• Hospitals
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
View Overview Report: https://www.insightaceanalytic.com/report/rnai-therapeutics-and-technology-market/2508
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release RNAi Therapeutics and Technology Market Key Players Analysis - Alnylam, Novartis, Novo Nordisk, Regulus therapeutics, miRagen therapeutics. here
News-ID: 3971572 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
4PL Logistics Market Revenue Report with Forecast to 2034
"4PL Logistics Market" in terms of revenue was estimated to be worth $59.6 Billion in 2024 and is poised to reach $133.3 Billion by 2034, growing at a CAGR of 8.5% from 2025 to 2034 according to a new report by InsightAce Analytic.
Get Free Sample Report @
https://www.insightaceanalytic.com/request-sample/1609
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global 4PL Logistics Market are:
• Rapid growth of automotive the…
Heavy-Duty Autonomous Vehicle Market Exclusive Trends Analysis with Forecast to …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Heavy-Duty Autonomous Vehicle Market- (By Application (Logistics, Public Transportation, Construction and Mining, Others), By Propulsion Type (Internal Combustion Engine Vehicles, Electric Vehicles), By Vehicle Type (Heavy Trucks, Heavy Buses, Roboshuttles), By Level of Autonomy (Fully Autonomous Vehicles, Semi-Autonomous Vehicles), By Sensor Type (LiDAR, RADAR, Camera, Others)) Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According…
E-Commerce Logistics Market Exclusive Report with Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-Commerce Logistics Market Size, Share & Trends Analysis Report By Service Type (Transportation And Warehousing) And Operational Area (International And Domestic)- Market Outlook And Industry Analysis 2034"
The global e-commerce logistics market is estimated to reach over USD 5340.2 billion by 2034, exhibiting a CAGR of 26.4% during the forecast period.
Request For Free Sample Pages:…
E-bikes Market Exclusive Report on the Latest Revenue and Future Scope
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-bikes Market Size, Share & Trends Analysis Report By Class (Class-I, Class-II, Class-III), Speed (Up to 25km/h, 25-45 km/h), Battery Type (Lithium-ion, Lithium-ion Polymer, Lead Acid), Mode (Pedal Assist, Throttle), Component (batteries, electric motors, frames with forks, wheels, crank gears, brake systems and motor controllers) , Motor Type (hub and mid), Usage (mountain, trekking, city/urban,…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
